Telematic Intervention for Reversing Frailty Among Older Patients with Aortic Stenosis Undergoing Transcatheter Aortic Valve Intervention. the TELE-FRAIL TAVI Clinical Trial
Launched by SPANISH SOCIETY OF CARDIOLOGY · Dec 15, 2024
Trial Information
Current as of June 29, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The TELE-FRAIL TAVI Clinical Trial is studying how a special program delivered through video calls can help older patients with a heart condition called aortic stenosis recover after a procedure called transcatheter aortic valve intervention (TAVI). The trial will compare two groups: one group will receive regular care, while the other group will participate in a telematic program that includes supervised exercise, nutrition support, and education about their health. The main goal is to see if this program can reduce frailty, which is a state of weakness, within three months after the TAVI procedure.
To participate in this trial, patients must be 75 years or older and have severe symptoms of aortic stenosis, along with signs of frailty measured by specific tests. Participants can expect to be randomly assigned to one of the two groups and will receive support through video calls from trained nurses over a 12-week period. The trial aims to improve not only frailty but also overall health outcomes, such as hospital stays and quality of life, helping older patients lead healthier lives after their heart procedure.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • older patients with aortic stenosis undergoing TAVI
- • baseline frailty criteria (SPPB \<10)
- Exclusion Criteria:
- • unability to sign informed consent
- • unability to complete geriatric assessment
- • unability to complete follow up
About Spanish Society Of Cardiology
The Spanish Society of Cardiology (Sociedad Española de Cardiología, SEC) is a leading professional organization dedicated to advancing cardiovascular health through research, education, and clinical practice. Committed to promoting excellence in cardiology, the SEC sponsors clinical trials aimed at enhancing the understanding and treatment of cardiovascular diseases. By fostering collaboration among healthcare professionals, researchers, and industry stakeholders, the SEC plays a pivotal role in developing innovative therapies and improving patient outcomes in Spain and beyond. Through its rigorous scientific approach, the society ensures that its sponsored trials adhere to the highest ethical and methodological standards, contributing valuable insights to the global cardiovascular community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Madrid, , Spain
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported